Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials.

Historically, the California-based pharma has remained tight-lipped when it comes to plans for MariTide, a monoclonal antibody linked to a pair of peptides designed to boost GLP-1 receptor activity while tamping down on the receptor for GIP.